All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Staying on track in a rapidly changing treatment landscape
Bookmark this article
During the 2020 Annual Meeting of the Society of Hematologic Oncology (SOHO), the AML Hub spoke to Eunice Wang, Roswell Park Comprehensive Cancer Center, Buffalo, US, about the rapidly changing treatment landscape for patients with AML.
Staying on track in a rapidly changing treatment landscape
A number of exciting advances have been made in treatment approaches to AML over the past few years. Firstly, the phase III VIALE-A study, established venetoclax + azacitadine as a superior front-line induction treatment for elderly or unfit patients with AML. Furthermore, the oral hypomethylating agent, CC-486, became the first FDA approved maintenance strategy for AML.
The outlook for patients with P53 mutant AML has also improved. Two targeted therapies, APR-246 and magrolimab, have demonstrated encouraging response rates in this setting; a major advance in the treatment approach for patients with P53 mutant AML.
Eunice Wang concludes by outlining promising immunotherapeutic approaches to AML, including the CD33/CD3 bispecific antibody, AMG 330.
Your opinion matters
15 votes - 79 days left ...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox